Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04530565 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04530565 · ClinicalTrials.gov record · last posted 2026-08-20

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Name: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults — clinical trial record (NCT04530565)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorNational Cancer Institute (NCI)

Started2021-01-25

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

Protocol amendment history 1 change detected by DataLookout

2026-03-31

Trial status changed: Recruiting → Active, Not Recruiting

Trial Details

NCT Number	NCT04530565
Lead Sponsor	National Cancer Institute (NCI)
Conditions	B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Enrollment	348 participants
Start Date	2021-01-25
Primary Completion	2028-07-01 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-20